<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862082</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.911</article-id><article-id pub-id-type="other">EPV0126</article-id><article-id pub-id-type="pii">S0924933824009118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Case Series: The use of Lithium in Bipolar Affective Disorder and End-Stage Renal Disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Corrigan</surname><given-names>K.</given-names></name><xref rid="aff2116" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0769" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Larkin</surname><given-names>D.</given-names></name><xref rid="aff2116" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Giusti</surname><given-names>G.</given-names></name><xref rid="aff2117" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gallagher</surname><given-names>M.</given-names></name><xref rid="aff2116" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Guerandel</surname><given-names>A.</given-names></name><xref rid="aff2116" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff2116"><sup>1</sup><institution>St Vincent&#x02019;s University Hospital</institution>, <city>Dublin</city>, <country>Ireland</country></aff><aff id="aff2117"><sup>2</sup><institution>The University of Pisa</institution>, <city>Pisa</city>, <country>Italy</country></aff><author-notes><corresp id="cor0769"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="886">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S439</fpage><lpage>S440</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824009118a.pdf"/><abstract><sec id="sec4623"><title>Introduction</title><p>Lithium&#x000a0;is a highly effective treatment in the management of Bipolar Affective Disorder (BPAD) however it is associated with increased risk of developing chronic kidney disease. There is a lack of clear guidance on alternative approaches to managing those individuals that require cessation of&#x000a0;lithium&#x000a0;due to progression to end stage renal disease (ESRD).</p></sec><sec id="sec4624"><title>Objectives</title><p>We discuss two patients with BPAD on&#x000a0;lithium&#x000a0;therapy who have developed ESRD. In both cases,&#x000a0;lithium&#x000a0;was discontinued due to ESRD, with alternatives trialled. In one case, the patient continues to be managed without&#x000a0;lithium, whereas in the second, a decision was made to recommence&#x000a0;lithium&#x000a0;at a low dose. We reviewed the literature to provide meaningful context to the cases.</p></sec><sec id="sec4625"><title>Methods</title><p>Case 1 This patient with a long history of BPAD and multiple medical co-morbidities experienced progressive decline in renal function. A decision was made to cease&#x000a0;lithium&#x000a0;therapy with close monitoring for signs of affective relapse. The patient was stabilised using a combination of sodium valproate and quetiapine. Since cessation of&#x000a0;lithium, the patient has required a significant increase in support from the CMHT and more frequent admissions to manage mood and anxiety symptoms that cause significant subjective distress.</p></sec><sec id="sec4626"><title>Results</title><p>
Case 2 This patient had a long history of stable BPAD, with no episodes of illness for over 30 years. Unfortunately they developed CKD and despite a significant reduction in&#x000a0;lithium&#x000a0;over time, they developed ESRD requiring haemodialysis.&#x000a0;Lithium&#x000a0;was discontinued leading to a manic relapse of BPAD requiring a prolonged admission and a combination of carbamezapine, olanzapine, escitalopram and clonazepam to stabilise their mental state. Following discharge home, their mental state failed to reach baseline and they reported significant anxiety symptoms and memory impairment. Following protracted assessment and support they were deemed unfit for renal transplant and a decision was then made by the patient, their family, nephrology and psychiatry to recommence&#x000a0;lithium&#x000a0;therapy whilst on haemodialysis. Their anxiety and functioning improved significantly following the reintroduction of low dose&#x000a0;lithium, allowing the withdrawal of other neuroleptics.</p></sec><sec id="sec4627"><title>Conclusions</title><p>Both cases required an individual approach to balance physical and mental health considerations. There are no clear markers to predict if a patient will respond to alternative mood stabilisers, nor is there a guarantee that kidney function will improve or stop declining when&#x000a0;lithium&#x000a0;is discontinued. Decisions should reflect patient preference and balance risks associated with relapse and of declining ESRD.</p></sec><sec id="sec4628"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>